watch
Imprimis Pharmaceuticals, Inc.

Imprimis Pharmaceuticals, Inc.

Sector: Pharmaceutical Preparations Region: CA, United States


: | Nasdaq: IMMY


Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding™ business model. The company is focused on patient outcomes and affordability and offers high quality lower-cost custom compounded drugs in all 50 states. Headquartered in San Diego, California, Imprimis owns and operates four dispensing facilities located in California, Texas, New Jersey and Pennsylvania. For more information about Imprimis, please visit the company website at www.ImprimisRx.com.

Investor Calendar

Latest Media

Warning! Third-party cookies must be enabled to view SlideShare presentations. ×

Having trouble?

Big Pharma Prioritises Profits Over Patients | Mark Baum | Oxford Union

Imprimis Pharmaceuticals, Inc. video

Big Pharma Prioritises Profits Over Patients | Mark Baum | Oxford Union

Imprimis Pharmaceuticals, Inc. video

Company offers $1 alternative to Pharma Bro’s drug

Imprimis Pharmaceuticals, Inc. video

New Cataract Surgery Option

Imprimis Pharmaceuticals, Inc. video

Rising Cost of Drugs

Executives

Mark L. Baum, Founder and CEO Board member
Mr. Baum is a founder, member of the board of directors and chief executive officer of Imprimis.
Beginning in December 2011, Mr. Baum established the corporate mission and vision for the company, focused on making drugs affordable again through its capital efficient Branded Compounding™ business model which provides patients, physicians and private and public payors with lower cost, high quality alternatives to branded and generic drugs. In the ten years prior to Mr. Baum’s involvement with Imprimis, he was the founder and managing director of TBLF, LLC, where he managed a series of three funds and acted as a principal investor. In 1999, Mr. Baum founded and served as the president of YesRx, and beginning in 1998, he practiced as a securities lawyer focused on public company reporting requirements and finance-related issues. He currently serves on the board of directors for Ideal Power, Inc. (NASDAQ: IPWR) where is the chairman of the audit committee, and is a senior advisor to Curology, Inc. Mr. Baum is an active participant in the national drug pricing and accessibility discussion, contributing through interviews and opinion writing for television, radio and print, advocating for policy changes to help ease the burden to patients and payors resulting from current drug pricing policies.
Andrew R. Boll, Vice-President, Accounting & Public Reporting
Mr. Boll has been the Chief Financial Officer of Imprimis Pharmaceuticals since February 2015. Mr. Boll oversees our accounting and financial reporting, investor relations, human resources and other operational departments. From February 2012 to January 2015, he was our Vice-President of Accounting and Public Reporting and was a consultant to our Company from December 2011 up to his hire date. Mr. Boll has led the accounting and certain financial efforts related to the restructuring and reorganization of Imprimis, and has overseen our pharmacy acquisitions, and integration processes of those pharmacies. Before joining Imprimis, from 2007 to 2011, Mr. Boll worked for BCGU, LLC, a privately-held fund manager, and its related entities, that specialized in capital venture-type investment opportunities. While at BCGU, he provided CFO/Controller consulting services to public company clients, compiling numerous SEC financial reports, and participating in several public company restructurings, financings and private to public mergers. Mr. Boll previously held various accounting roles at Welsh Companies, LLC, a privately held commercial real estate company, its fund and its other subsidiaries (during 2004 to 2007). Mr. Boll is a CFA charterholder, Certified Management Accountant and earned his B.S. degree in Corporate and Public Finance. He is a member of the Institute of Management Accountants, the CFA Institute, and the CFA Society of San Diego.
John Saharek, Vice-President of Commercialization, Ophthalmology
Mr. Saharek is a senior healthcare industry executive with over 30 years of broad experience developing and commercializing pharmaceutical, biotech, surgical device and diagnostic product portfolios. His results-oriented record of achievement includes designing and executing strategic commercial plans, building strong sustainable brands, launching new products, leading high performing teams and delivering outstanding results for a variety of healthcare companies. Over the past 15 years he has been focused in the ophthalmology segment where he has established valuable relationships with key opinion leaders and industry contacts. Mr. Saharek has been our Chief Commercial Officer since February 2015. Prior to that he served as our Vice-President of Commercialization, Ophthalmology since November 2012. Before joining Imprimis, he served as Head of U.S. Marketing and Strategy for ThromboGenics Inc., developing the commercial strategy and building a team to launch a new biologic into the US market. Prior to that he was Vice President, Business Development at SurModics Inc., working with both large and small pharmaceutical companies on multi-platform drug delivery initiatives in the U.S. and internationally. Early on in his career he held positions of increasing responsibility in both marketing and sales at a number of companies, including his tenure with Bausch & Lomb. Mr. Saharek has a Master’s of Business Administration from the University of Hartford and a Bachelor’s degree from Central Connecticut State University.
Gary Seelhorst, Vice-President, Corporate Development
Mr. Seelhorst has over 17 years of clinical and corporate development experience with both large-cap pharmaceutical companies (e.g. Eli Lilly and Pfizer) as well as start-up ventures including extensive capital raising, licensing, and M&A transactions. Most recently, Gary has worked as a management consultant for several start-ups both raising capital and setting up strategic joint ventures in both the pharmaceutical and nanotechnology spaces. In 2012, he worked for HUYA Biosciences International in Global Business Development setting up both in-licensing and strategic partnerships primarily in China. From 2006 to 2011, he worked as VP of Business Development and Strategic Marketing for Naviscan, a medical device and biotech start-up wherein he helped to build up both the commercial side of the business as well as execute many in- and out-licensing deals which lead to some significant partnerships with Fortune 500 companies, i.e. Johnson & Johnson, Hologic, and CR Bard. From 1998 to 2006, Gary worked at Pfizer in various positions in Clinical Development as well as Corporate Development, helping to initiate a burgeoning in-licensing and M&A campaign which resulted in several large M&A transactions. From 1996 to 1998, Gary worked as a Medical Writer for Eli Lilly with his entire tenure devoted to writing a successfully approved NDA for Prozac®. Gary received an MBA from the University of Michigan, an MS from Indiana University, and a Bachelor’s degree from the University of California at San Diego.
Clayton D. Edwards, Senior Vice President, Operations
Mr. Edwards joined Imprimis in August 2016 as Senior Vice President of Operations where he oversees the company’s pharmacy operations, including production, dispensing and customer service. Mr. Edwards is a healthcare executive with over 30 years of experience developing and operationalizing complex healthcare products and services. Prior to joining Imprimis, he was the Senior Vice President of Home Delivery Pharmacy and Prior Authorization for OptumRx, a UnitedHealthcare company, where he led an $18B P&L business segment, developing and improving Traditional, Specialty and Compounding Pharmacy, Prior Authorization, financial infrastructure, enterprise-wide information technology and robotic systems, as well as productivity improvement measures. At OptumRx, Mr. Edwards grew the mail order pharmacy business to over 32 million prescriptions annually with six-sigma dispensing accuracy, directing a global staff of over 5,500 employees in pharmacy operations, prior authorization and appeals. Mr. Edwards also led the development of a compounding formulary and network strategy for member pharmacies. Earlier in his career, he held various executive level positions at Doctor Diabetic Pharmacy/Sanare, Liberty Medical and Medco Health Solutions. He actively serves on the Albany College of Pharmacy & Health Sciences Dean’s Advisory Counsel, where he graduated with his Pharmacy degree. He also has a Master’s degree in Business Administration from St. Joseph’s University.
Eric Rice, Vice President, Client Relations
Mr. Rice has been the Vice President of Client Relations at Imprimis since July 2016 and is responsible for implementing new processes to improve efficiencies with the ultimate goal of building Imprimis’ customer service department into a center of excellence.
Mr. Rice brings over 20 years of experience managing customer contact centers of varying sizes. Mr. Rice previously served as Vice-President of Philidor Rx Services, where he was responsible for the oversight of its call center operations comprised of over 550 agents, 40 supervisors, a workforce management, and quality and mentor teams. In his two years in that role he oversaw department growth from 60 to 600+ professionals and built a center of excellence that supported 10X dispensing volume growth. Previously, he served as Director of Strategy and Operation for Comcast Business Class. Before joining Comcast, Rice received his start in contact centers during his 20-year career with Prudential. Across that span, he held a variety of call center related positions, culminating with oversight of 20 call center departments across multiple locations.
Pramod Sharma, Vice President, Quality
Mr. Sharma has been the Vice President of Quality since August 2016 and oversees the expansion of all Imprimis quality systems in line with the highest pharmaceutical and compounding industry standards. Mr. Sharma has more than 15 years of quality assurance and quality control leadership skills, as well as laboratory management experience. He oversees all Imprimis quality programs. Included in these responsibilities is continuing to expand all Imprimis quality systems in line with the highest pharmaceutical and compounding industry standards. Prior to joining Imprimis, Mr. Sharma was the Senior Director of Research and Development Quality at Alvogen where he oversaw the quality production of sterile and non-sterile injectable, oral, topical, transdermal, and transmucosal drugs. He also served as the Senior Director of Quality at Albany Molecular Research and spent 7 years holding various positions at Akorn Inc., including the Executive Director of Quality Compliance, where he ensured successful adherence to cGMP requirements in multiple facilites, contributed to several successful NDA, ANDA and ANADA FDA submissions and represented Akorn in many FDA inspections of aseptic production processes. Mr. Sharma received his Ph.D. in Microbiology from the University of Oklahoma and performed postdoctoral research at Stanford University and Brookhaven National Laboratory.
Sanjay Samudre, Director of Manufacturing
Mr. Samudre has been the Director of Manufacturing at Imprimis since May 2016 where he oversees supply chain and production while adding automation and scalability to many of the company’s core compounded formulations. He brings to the company more than two decades of pharmaceutical supply chain, production management and operations experience. Prior to joining Imprimis, Mr. Samudre was Director of Operations at Teligent Pharma (formerly IGI Labs) where he provided leadership in functional pharmaceutical areas including manufacturing, packaging, engineering, process improvements and supply chain. He previously served as Plant Manager of Mediatech Inc., a division of Corning Life Sciences and as Production Manager at Qualitest Pharmaceuticals Inc., a subsidiary of Endo Health Solutions. Mr. Samudre also worked for Ciba Vision, the eye care unit of Novartis AG, as Production Manager to oversee manufacturing, filling and packaging operations. He has also held various positions with leading pharmaceutical companies Patheon, Apotex and Johnson and Johnson across Canada and India. Mr. Samudre received a Degree in Pharmacy from the University of Pune India in 1994.

News & Analysis